Vectura In Asthma Collaboration With Novartis's Sandoz
June 28 2017 - 12:54PM
Dow Jones News
LONDON-- Medical inhaler company Vectura Group PLC (VEC.LN)
Wednesday announced a collaboration with Sandoz, a division of
Swiss drug giant Novartis AG (NVS), to develop a generic version of
an inhaler therapy for asthma and chronic obstructive pulmonary
disease.
Vectura will receive an initial payment of $5 million from
Sandoz and up to $5 million more depending on targets. It expects
its research and development costs to be less than $20 million.
-Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter:
@RoryGallivan
(END) Dow Jones Newswires
June 28, 2017 12:39 ET (16:39 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Sep 2023 to Sep 2024